Home / Stock ratings / Healthcare Stocks / HCA
Stock rating · Services-General Medical & Surgical Hospitals, Nec
HCA Healthcare, Inc. (HCA) Stock Rating & Analysis
As of October 6, 2026, MELANY rates HCA Healthcare, Inc. 65 out of 100 (Hold). Its highest factor score is catalyst setup at 91, and its lowest is price momentum at 48.
MELANY ratingRated 2026-10-06HCA · composite score
About HCA Healthcare, Inc.
HCA Healthcare is a Nashville-based healthcare provider that runs the largest group of acute-care hospitals in the US. As of December 2025, it owned and operated 190 hospitals and over 2,500 outpatient facilities across 19 states, plus a small presence in the United Kingdom.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why HCA scores 65/100
HCA's 8 factor scores run from 48 to 91, and 2 of them sit above its composite of 65. Here is how HCA breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 14.9x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
- Gross margin 43%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +7%
- Earnings in 21 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 21 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How HCA compares
As of October 7, 2026, HCA Healthcare, Inc. is tied for 14th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for HCA
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
HCA Healthcare, Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds HCA's momentum and catalyst factors above.
Tracking HCA
HCA Healthcare, Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Add HCA to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates HCA
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. HCA Healthcare, Inc.'s 65/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about HCA
Is HCA Healthcare, Inc. (HCA) a buy?
As of 2026-10-06, MELANY rated HCA Healthcare, Inc. Hold with a composite score of 65/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is HCA Healthcare, Inc.'s MELANY score?
HCA Healthcare, Inc. (HCA) has a MELANY composite score of 65/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the HCA stock rating calculated?
MELANY scores HCA from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy HCA Healthcare, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates HCA Healthcare, Inc. (HCA) Hold with a composite of 65/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the HCA stock price forecast?
MELANY does not publish price targets or forecasts for HCA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 65/100 across eight factors for HCA Healthcare, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is HCA stock overvalued or undervalued?
MELANY's valuation factor currently reads 64/100 for HCA Healthcare, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives HCA's read.
What price should I buy HCA at?
MELANY is not flagging a fresh entry for HCA at its current Hold rating, so there is no entry zone to publish right now. Add HCA to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying HCA stock?
The top risks MELANY currently flags for HCA Healthcare, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is HCA Healthcare, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 54/100 for HCA Healthcare, Inc., and earnings track record, at 77/100. The 65/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will HCA stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 48/100 for HCA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this HCA rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores HCA continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, HCA included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.